# SGLT2i, Hepatic Glucose Production, and SNS

> **NCT07053293** · EARLY_PHASE1 · RECRUITING · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 22 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Empagliflozin 25 MG

## Key facts

- **NCT ID:** NCT07053293
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-30
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2025-07-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07053293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07053293, "SGLT2i, Hepatic Glucose Production, and SNS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07053293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*